Lacosamide
Also known as: Erlosamide, Harkoseride, SPM927, Vimpat
Lacosamide is an antiepileptic drug that is under investigation for adjunctive therapy in partial seizure with or without secondary generalisation in patients with epilepsy aged 16 years and older.
Primary Characteristics
Lacosamide is also known as Erlosamide, Harkoseride, SPM927, Vimpat.
It is classified in Anti-epileptic Agent , Anti-epileptic Agent pharmacological group.
Pharmacokinetics
None recorded.
Advertisement
Indications
Lacosamide is primarily indicated in conditions like 5-fu therapy.
Contraindications
None recorded.
Dosage
Lacosamide's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 125 mg | 125 mg | Every 12h | PO and IV | When switching from oral VIMPAT, the initial total daily intravenous dosage of VIMPAT should be equivalent to the total daily dosage and frequency of oral VIMPAT. At the end of the intravenous treatment period, the patient may be switched to VIMPAT oral administration at the equivalent daily dosage and frequency of the intravenous administration. |
| Paediatric Dosage (20kg) | ||||
| 0 – 0 | — | — | ||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
The signs and symptoms that are produced after acute overdosage of Lacosamide are Drowsiness, Drowsiness, balance problem, Ataxia, Dizziness, Double Vision, Depression , shaking of hands or feet.
Lacosamide is known to cause more or less tolerable side effects which are usually transient. These include Diarrhea, Headache, Local irritation, Tremor, Vomiting .
Warnings / Precautions
Available Brands
Drug Classification
- 1.5 — Anticonvulsants and Antiepileptics